TW202045495A - １－（１－側氧基－１，２－二氫異喹啉－５－基）－５－（三氟甲基）－ｎ－（２－（三氟甲基）吡啶－４－基）－１ｈ－吡唑－４－甲醯胺一水合物的結晶形式 - Google Patents

１－（１－側氧基－１，２－二氫異喹啉－５－基）－５－（三氟甲基）－ｎ－（２－（三氟甲基）吡啶－４－基）－１ｈ－吡唑－４－甲醯胺一水合物的結晶形式 Download PDF

Info

Publication number
TW202045495A
TW202045495A TW109105620A TW109105620A TW202045495A TW 202045495 A TW202045495 A TW 202045495A TW 109105620 A TW109105620 A TW 109105620A TW 109105620 A TW109105620 A TW 109105620A TW 202045495 A TW202045495 A TW 202045495A
Authority
TW
Taiwan
Prior art keywords
crystalline form
compound
cancer
disorder
disease
Prior art date
Application number
TW109105620A
Other languages
English (en)
Chinese (zh)
Inventor
卡莉娜 雷茲
克里斯托弗 金普
羅伯特 吉爾特曼
魏昊娟
周鵬
Original Assignee
比利時商健生藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商健生藥品公司 filed Critical 比利時商健生藥品公司
Publication of TW202045495A publication Critical patent/TW202045495A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW109105620A 2019-02-22 2020-02-21 １－（１－側氧基－１，２－二氫異喹啉－５－基）－５－（三氟甲基）－ｎ－（２－（三氟甲基）吡啶－４－基）－１ｈ－吡唑－４－甲醯胺一水合物的結晶形式 TW202045495A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019075834 2019-02-22
WOPCT/CN2019/075834 2019-02-22

Publications (1)

Publication Number Publication Date
TW202045495A true TW202045495A (zh) 2020-12-16

Family

ID=69723907

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109105620A TW202045495A (zh) 2019-02-22 2020-02-21 １－（１－側氧基－１，２－二氫異喹啉－５－基）－５－（三氟甲基）－ｎ－（２－（三氟甲基）吡啶－４－基）－１ｈ－吡唑－４－甲醯胺一水合物的結晶形式

Country Status (21)

Country Link
US (1) US12269813B2 (https=)
EP (1) EP3927696B1 (https=)
JP (1) JP2022523368A (https=)
KR (1) KR20210131371A (https=)
CN (1) CN113474339B (https=)
AU (1) AU2020226723B2 (https=)
BR (1) BR112021016400A2 (https=)
CA (1) CA3129623A1 (https=)
EA (1) EA202192320A1 (https=)
EC (1) ECSP21067828A (https=)
ES (1) ES2966132T3 (https=)
IL (1) IL285675A (https=)
JO (1) JOP20210227A1 (https=)
MA (1) MA55019A (https=)
MX (1) MX2021010133A (https=)
PE (1) PE20212067A1 (https=)
PH (1) PH12021552018A1 (https=)
SG (1) SG11202108909SA (https=)
TW (1) TW202045495A (https=)
UY (1) UY38592A (https=)
WO (1) WO2020169736A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3953345B1 (en) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Pyridine rings containing derivatives as malt1 inhibitors
TW202227067A (zh) 2020-08-21 2022-07-16 比利時商健生藥品公司 Ｍａｌｔ１抑制劑之無定形形式及其配製物
BR112023017648A2 (pt) 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Terapia de combinação com o uso de um inibidor de malt1 e um inibidor de btk
BR112023017689A2 (pt) 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n­(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida)
MX2024001840A (es) 2021-08-09 2024-02-28 Janssen Pharmaceutica Nv Composiciones para usar en el tratamiento de neoplasias de celulas b.
WO2025073968A1 (en) 2023-10-06 2025-04-10 Ionctura Sa Combination of roginolisib with a malt1-gls inhibitor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004098515A2 (en) 2003-04-30 2004-11-18 Agensys, Inc. Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer
JP2009533327A (ja) * 2006-03-22 2009-09-17 バーテックス ファーマシューティカルズ インコーポレイテッド 増殖性疾患を処置するためのｃ−ＭＥＴキナーゼ阻害剤
CN101583601B (zh) 2007-01-17 2013-06-05 香港科技大学 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物
WO2011036885A1 (ja) * 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
ES2539379T3 (es) 2010-06-22 2015-06-30 Basf Se Procedimiento de preparación de 4-hidroxipiridinas
JP6231085B2 (ja) * 2012-05-31 2017-11-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト アミノキナゾリン誘導体及びピリドピリミジン誘導体
SG11201607895PA (en) 2014-05-28 2016-12-29 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
AU2015300966A1 (en) 2014-08-08 2017-02-16 Janssen Pharmaceutica Nv Bruton's tyrosine kinase inhibitor combinations and uses thereof
WO2016209688A1 (en) * 2015-06-24 2016-12-29 University Of Florida Research Foundation, Incorporated Compositions for the treatment of cancer and uses thereof
AU2016352813B2 (en) 2015-11-13 2019-09-19 Novartis Ag Novel pyrazolo pyrimidine derivatives
US10882841B2 (en) 2016-03-01 2021-01-05 University Of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
US20200009135A1 (en) 2017-02-01 2020-01-09 Medivir Ab Therapeutic applications of malt1 inhibitors
AU2018395291A1 (en) 2017-12-28 2020-07-30 The General Hospital Corporation Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
EP3756268A1 (de) 2018-02-23 2020-12-30 Industrieanlagen-Betriebsgesellschaft mbH Vorrichtung zum erzeugen eines magnetfelds, insbesondere für ein induktives ladesystem, und primäreinrichtung eines induktiven ladesystems zum dynamischen aufladen von fahrzeugen
WO2021138298A1 (en) 2019-12-30 2021-07-08 Rheos Medicines, Inc. Malt1 modulators and uses thereof
TW202227067A (zh) * 2020-08-21 2022-07-16 比利時商健生藥品公司 Ｍａｌｔ１抑制劑之無定形形式及其配製物

Also Published As

Publication number Publication date
UY38592A (es) 2020-08-31
WO2020169736A1 (en) 2020-08-27
IL285675A (en) 2021-10-31
EP3927696B1 (en) 2023-10-18
PH12021552018A1 (en) 2022-09-19
KR20210131371A (ko) 2021-11-02
ES2966132T3 (es) 2024-04-18
CN113474339B (zh) 2025-02-25
ECSP21067828A (es) 2021-11-18
EA202192320A1 (ru) 2021-11-16
AU2020226723A1 (en) 2021-08-19
CN113474339A (zh) 2021-10-01
EP3927696A1 (en) 2021-12-29
EP3927696C0 (en) 2023-10-18
SG11202108909SA (en) 2021-09-29
US20220127249A1 (en) 2022-04-28
US12269813B2 (en) 2025-04-08
MX2021010133A (es) 2021-09-23
JP2022523368A (ja) 2022-04-22
CA3129623A1 (en) 2020-08-27
BR112021016400A2 (pt) 2021-10-13
AU2020226723B2 (en) 2025-01-23
MA55019A (fr) 2021-12-29
JOP20210227A1 (ar) 2021-08-18
PE20212067A1 (es) 2021-10-26

Similar Documents

Publication Publication Date Title
TW202045495A (zh) １－（１－側氧基－１，２－二氫異喹啉－５－基）－５－（三氟甲基）－ｎ－（２－（三氟甲基）吡啶－４－基）－１ｈ－吡唑－４－甲醯胺一水合物的結晶形式
CN111770914B (zh) 作为神经激肽-1受体拮抗剂的化合物及其用途
CN105793245B (zh) 药物化合物
CN114867531B (zh) Egfr抑制剂
CN101759693B (zh) 苯骈异恶唑哌啶衍生物及在制备镇痛、镇静药物中的应用
JP5924453B2 (ja) 二環式含窒素芳香族ヘテロ環アミド化合物
CN112759544B (zh) 3-(二甲氨基甲基)哌啶-4-醇衍生物制备方法和药物用途
WO2018072742A1 (zh) 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
CN104169277B (zh) 极光激酶和flt3激酶调节剂
JP7565118B2 (ja) （ｓ，ｅ）－４－（ジメチルアミノ）－ｎ－（３－（４－（２－ヒドロキシ－１－フェネチルアミノ）－６－フェニルフロ［２，３－ｄ］ピリミジン－５－イル）フェニル）ブタ－２－エナミド遊離塩基の結晶形
CN101993417A (zh) 磷酸二甲啡烷的稳定新晶型
HK40052643A (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
WO2023154338A1 (en) Solid forms of a parp14 inhibitor
EA045924B1 (ru) Кристаллическая форма моногидрата 1-(1-оксо-1,2-дигидроизохинолин-5-ил)-5-(трифторметил)-n-(2-(трифторметил)пиридин-4-ил)-1h-пиразол-4-карбоксамида
TW201829398A (zh) 酪胺酸蛋白激酶調節劑、晶型及其用途
JP2025501195A (ja) アミノピリミジン系化合物の塩及びその用途
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
CN118451071A (zh) 表皮生长因子受体抑制剂的结晶多晶型物及其组合物和方法
JP2024544019A (ja) 化合物
HK40094095A (zh) (s，e)-4-(二甲胺基)-n-(3-(4-(2-羟基-1-苯乙胺基)-6-苯基呋喃并[2，3-d]嘧啶-5-基)苯基)丁-2-烯醯胺游离硷的晶型
CN116354950A (zh) 氨基嘧啶类化合物的盐及其用途
KR20210155806A (ko) Pi3k 저해제의 결정다형 및 이의 제조방법
WO2019001551A1 (zh) 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法